New pill targets tough KRAS cancers in early trial

NCT ID NCT06243354

First seen Jan 31, 2026 · Last updated May 14, 2026 · Updated 18 times

Summary

This study tests an experimental drug called HYP-2090PTSA in people with advanced solid tumors that have a specific genetic change called a KRAS mutation. The goal is to find the safest dose and see if the drug can shrink tumors. About 257 adults will take part in two phases: first to check safety and dosing, then to measure how well the drug works.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TOLERABILITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Fujian Provincial Cancer Hospital

    RECRUITING

    Fuzhou, Fujian, 350000, China

    Contact

  • Hunan Provincial Cancer Hospital

    NOT_YET_RECRUITING

    Changsha, Hunan, 410000, China

    Contact

  • Shandong Provincial Cancer Hospital

    NOT_YET_RECRUITING

    Jinan, Shandong, 250000, China

    Contact

  • Shanghai Pulmonary Hospital

    RECRUITING

    Shanghai, Shanghai Municipality, 200000, China

    Contact

  • The first Hospital of China Medical University

    NOT_YET_RECRUITING

    Shenyang, Liaoning, 110000, China

    Contact

  • West China Hospital of Sichuan University

    RECRUITING

    Chengdu, Sichuan, 610000, China

    Contact

Conditions

Explore the condition pages connected to this study.